Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats.
Zikra ZulfiqarFawad Ali ShahShagufta ShafiqueAbdullah AlattarTahir AliArooj Mohsin AlviSajid RashidShupeng LiPublished in: Journal of inflammation research (2020)
Our results demonstrated that the novel FDA-approved medications attenuate ischemic stroke-induced neuronal degeneration, possibly by inhibiting JNK3. Being FDA-approved safe medications, the use of these drugs can be clinically translated for ischemic stroke-associated brain degeneration and other neurodegenerative diseases associated with oxidative stress and neuroinflammation.
Keyphrases
- drug administration
- cerebral ischemia
- signaling pathway
- oxidative stress
- induced apoptosis
- diabetic rats
- lipopolysaccharide induced
- traumatic brain injury
- atrial fibrillation
- cell death
- drug induced
- lps induced
- subarachnoid hemorrhage
- cognitive impairment
- high glucose
- blood brain barrier
- brain injury
- dna damage
- white matter
- resting state
- endoplasmic reticulum stress
- inflammatory response
- multiple sclerosis
- functional connectivity
- heat shock protein